Company: SCLXW
Filing Date: 2025-01-17
Form Type: 10-Q
Source: 0000950170-25-006755
Chunk: 324

Company: Scilex Holding Co
Filing Date: 2025-01-17
Form: 10-Q
Item: Item 8
Chunk 324
---
    4,319

    Net operating costs and expenses:

    Cost of revenue

    3,768

    3,392

    376

    Research and development

    2,349

    4,072

    (1,723
    )

    Selling, general and administrative

    29,734

    40,431

    (10,697
    )

    Intangible amortization

    1,002

    1,027

    (25
    )

    Legal settlements

    (2,500
    )

    —

    (2,500
    )

    Total net operating costs and expenses

    34,353

    48,922

    (14,569
    )

    Loss from operations

    (19,917
    )

    (38,805
    )

    18,888

    Other (income) expense, net:

    Gain on derivative liability

    (18,108
    )

    (4,245
    )

    (13,863
    )

    Change in fair value of debt and liability instruments

    1,957

    449

    1,508

    Interest expense, net

    576

    513

    63

    Loss on foreign currency exchange

    46

    7

    39

    Total other expense, net

    (15,529
    )

    (3,276
    )

    (12,253
    )

    Loss before income taxes

    (4,388
    )

    (35,529
    )

    31,141

    Income tax benefit

    —

    —

    0

    Net loss
     
    $
    (4,388
    )
     
    $
    (35,529
    )
     
    $
    31,141

Comparison of the Three Months Ended September 30, 2024 and 2023

Net Revenue

Net revenue for the three months ended September 30, 2024 and 2023 was $14.4 million and $10.1 million, respectively. The increase of $4.3 million was driven by the increase in gross product sales of ELYXYB by approximately 54% driven by an increase in the sales volume and a standard industry annual price increase, and sales of GLOPERBA commencing in June 2024,